Fundraising Fox
/Companies
Sign in

EdenRoc Sciences

Worcester, US · Founded 2016 · Delaware LLC

Find your way into EdenRoc Sciences

46 people in our graph share verified history with the EdenRoc Sciences team — schools, employers, funds. One of them is your warm intro.

Raman Kapurunlockedknows Christopher McDoniel · together at Tectura (overlapped)
knows the team · via EdenRoc Sciences, LLC
×9knows the team · via Plante & Moran, PLLC
knows the team · via Walsh College

EdenRoc Sciences is a life sciences holding company that founds and funds subsidiary biotechnology companies addressing diseases of aging, with assets spanning genomic detection, clinical-stage pharmaceuticals, forensics, and biologic-based consumer products. Its subsidiaries operate autonomously while sharing board oversight and centralized business functions, and its work spans diagnostics and therapeutics across biotech and healthcare markets.

BiotechHealthtechLongevity

Founders & leadership

CWChristopher Wibbleman
Christopher WibblemanExecutive
ME
Mathew EasterdayExecutive
CMChristopher McDoniel
Christopher McDonielExecutiveChristopher McDoniel leads fundraising, investor relations, and finance functions for EdenRoc Sciences and its portfolio companies. He previously worked in public accounting focusing on mergers and acquisitions, partnership taxation, and high-net-worth individual planning, and served as tax manager during the General Motors bankruptcy restructuring.
ESEdward Schulak
Edward SchulakExecutive
DS
David SinclairNamed on SEC filing

Board

JT
J. Taylor CrandallBoard director
TD
Todd DickinsonBoard director
JA
Jason AndersonBoard director
CB
Carlos BustamanteBoard director
EG
Ed GreenBoard director

Reported raises · per SEC filings

Form D private placements

$219.9M disclosed across 10 rounds · 2016–2024

▶$2.8MraisedNov 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward SchulakExecutive Officer, Director
  • Todd DickinsonDirector
  • Christopher WibblemanDirector
  • J. Taylor CrandallDirector
  • Christopher McDonielExecutive Officer
  • Mathew EasterdayExecutive Officer
  • David SinclairDirector
Offering amount
$50M
Amount sold
$2.8M
First sale
Nov 2024
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$64.2MraisedJul 2024 · 50 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher WibblemanDirector
  • David SinclairDirector
  • J. Taylor CrandallDirector
  • Mathew EasterdayExecutive Officer
  • Christopher McDonielExecutive Officer
  • Edward SchulakExecutive Officer, Director
  • Todd DickinsonDirector
Offering amount
$64.2M
Amount sold
$64.2M
First sale
Jun 2022
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35.9MraisedMay 2022 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mathew EasterdayExecutive Officer
  • J.Taylor CrandallDirector
  • Todd DickinsonDirector
  • Edward SchulakExecutive Officer
  • David SinclairDirector
  • Christopher WibblemanDirector
Offering amount
$35.9M
Amount sold
$35.9M
First sale
May 2021
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18MraisedNov 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward SchulakExecutive Officer, Director
  • Carlos BustamanteDirector
  • Gregory LucierDirector
  • Mathew EasterdayExecutive Officer
  • J. Taylor CrandallDirector
  • Todd DickinsonDirector
  • David SinclairDirector
Offering amount
$18M
Amount sold
$18M
First sale
Aug 2020
Incorporated
Limited Liability Company, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.6MraisedJul 2020 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward SchulakExecutive Officer, Director
  • Carlos BustamanteDirector
  • Mathew EasterdayExecutive Officer
  • Todd DickinsonDirector
  • Jason AndersonDirector
  • David SinclairDirector
Amount sold
$17.6M
First sale
Jan 2020
Incorporated
Limited Liability Company, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedJul 2019 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward SchulakExecutive Officer, Director
  • Mathew EasterdayExecutive Officer
  • Todd DickinsonDirector
  • Jason AndersonDirector
  • Carlos BustamanteDirector
  • David SinclairDirector
Offering amount
$47.5M
Amount sold
$8M
First sale
Jul 2019
Incorporated
Limited Liability Company, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.5MraisedFeb 2019 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mathew EasterdayExecutive Officer
  • David SinclairDirector
  • Jason AndersonDirector
  • Carlos BustamanteDirector
  • Todd DickinsonDirector
  • Edward SchulakExecutive Officer, Director
Offering amount
$13.5M
Amount sold
$13.5M
First sale
Feb 2019
Incorporated
Limited Liability Company, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedMar 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carlos BustamanteDirector
  • Mathew EasterdayExecutive Officer
  • Jason AndersonDirector
  • Edward SchulakExecutive Officer, Director
  • Todd DickinsonDirector
  • David SinclairDirector
Offering amount
$15M
Amount sold
$15M
First sale
Mar 2018
Incorporated
Limited Liability Company, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
IQVIA15 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Fortis Life Sciences12 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Aro Biotherapeutics11 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies competing with EdenRoc Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does EdenRoc Sciences do?
EdenRoc Sciences is a life sciences holding company that founds and funds subsidiary biotechnology companies addressing diseases of aging, with assets spanning genomic detection, clinical-stage pharmaceuticals, forensics, and biologic-based consumer products. Its subsidiaries operate autonomously while sharing board oversight and centralized business functions, and its work spans diagnostics and therapeutics across biotech and healthcare markets.
How much funding has EdenRoc Sciences raised?
EdenRoc Sciences has disclosed $219.9M raised across 10 rounds.
Where is EdenRoc Sciences headquartered?
EdenRoc Sciences is headquartered in Worcester, US.